It is a privilege to present the Federation’s Annual Report for 2024, capturing a year defined by resilience, innovation, and progress in advancing TIF’s mission to improve the lives of people living with thalassaemia and other rare anaemias worldwide.
It is a privilege to present the Federation’s Annual Report for 2024, capturing a year defined by resilience, innovation, and progress in advancing TIF’s mission to improve the lives of people living with thalassaemia and other rare anaemias worldwide.
In 2024, TIF strengthened its position as a trusted partner in global health through the renewal of its Official Relations with the World Health Organization (WHO), underscoring the Federation’s enduring commitment to shaping international health priorities and policies.
Among this year’s key milestones, TIF was honoured to receive the HemaSphere Award for its 2021 Guidelines on Transfusion-Dependent Thalassaemia, acknowledging their impact on global clinical practice and patient care. The launch of the TIF Collaborating Centres Programme, with the certification of the first two centres of excellence, marked a pivotal step toward recognising best practices and fortifying healthcare systems worldwide.
TIF’s Annual Capacity Building Workshop brought together 140 participants from 34 countries, fostering peer learning and skill development among patient leaders and healthcare professionals. Equally significant were the inaugural Rare Anaemias International Network (RAIN) Summit and the Regional Summit on Haemoglobin Disorders in the Middle East and North Africa (MENA), both of which strengthened regional collaboration and advocacy efforts.
In parallel, TIF continued to embrace innovation with the introduction of the TIF AI Knowledge Chatbot, designed to enhance multilingual access to reliable, evidence-based educational resources, ensuring information remains readily available to patients and professionals alike.
Throughout 2024, the Federation’s unwavering commitment to empowering patients, reducing inequalities, and promoting equitable access to both basic and novel therapies remained central to its activities. Guided by its strategic vision, TIF continues to champion the rights of individuals with haemoglobin disorders, ensuring that their voices are heard across all levels of decision-making.
Reflecting on 2024’s achievements, we express our deepest gratitude to TIF’s Members, healthcare professionals, partners, and supporters, whose dedication and collaboration make our shared progress possible. Together, we remain steadfast in our pursuit of a future where every patient enjoys the highest attainable standard of health and quality of life.
